Suppliers and packagers for generic pharmaceutical drug: NALOXONE HYDROCHLORIDE

NALOXONE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hikma	NALOXONE	naloxone hydrochloride	INJECTABLE;INJECTION	070299	ANDA	Hikma Pharmaceuticals USA Inc.	0641-6132-25	25 VIAL in 1 CARTON (0641-6132-25) / 1 mL in 1 VIAL (0641-6132-01)	1986-09-24
Hikma	NALOXONE	naloxone hydrochloride	INJECTABLE;INJECTION	070299	ANDA	Hikma Pharmaceuticals USA Inc.	0641-6260-25	25 VIAL in 1 CARTON (0641-6260-25) / 1 mL in 1 VIAL (0641-6260-01)	2022-03-01
Hikma	NALOXONE	naloxone hydrochloride	INJECTABLE;INJECTION	070299	ANDA	HF Acquisition Co LLC, DBA HealthFirst	51662-1671-3	25 VIAL in 1 CARTON (51662-1671-3) / 1 mL in 1 VIAL (51662-1671-1)	1986-09-24
Hikma	NALOXONE	naloxone hydrochloride	INJECTABLE;INJECTION	070299	ANDA	Medical Purchasing Solutions, LLC	71872-7009-1	1 VIAL in 1 BAG (71872-7009-1) / 1 mL in 1 VIAL	1986-09-24
Hikma	NALOXONE	naloxone hydrochloride	INJECTABLE;INJECTION	070299	ANDA	Civica, Inc.	72572-450-25	25 VIAL in 1 CARTON (72572-450-25) / 1 mL in 1 VIAL (72572-450-01)	2019-11-11
Baxter Hlthcare Corp	NALOXONE HYDROCHLORIDE	naloxone hydrochloride	INJECTABLE;INJECTION	214785	ANDA	Baxter Healthcare Corporation	36000-308-10	10 VIAL, SINGLE-DOSE in 1 CARTON (36000-308-10) / 1 mL in 1 VIAL, SINGLE-DOSE (36000-308-01)	2021-01-29

Naloxone Hydrochloride: Key Suppliers and Patent Landscape

Last updated: February 19, 2026

Naloxone hydrochloride is a critical pharmaceutical ingredient, primarily used as an opioid antagonist to reverse opioid overdose. The market for naloxone hydrochloride is characterized by a concentrated supplier base and an evolving patent landscape, influenced by both originator patents and subsequent process patents.

What is Naloxone Hydrochloride?

Naloxone hydrochloride is a potent, short-acting opioid antagonist. It binds to opioid receptors with higher affinity than most opioids, blocking their effects. This action is reversible, meaning naloxone hydrochloride will detach from the receptor, allowing opioids to rebind, and thus its effects are temporary. The drug is administered via injection, nasal spray, and auto-injector. Its primary indication is the emergency treatment of known or suspected opioid overdose. The chemical structure of naloxone hydrochloride is $\text{C}{19}\text{H}{21}\text{NO}_4 \cdot \text{HCl}$ with a molecular weight of $367.84 \text{ g/mol}$.

Who are the Primary Manufacturers of Naloxone Hydrochloride API?

The active pharmaceutical ingredient (API) for naloxone hydrochloride is produced by a limited number of global manufacturers. These suppliers are critical to the supply chain for both generic and branded naloxone products.

• Narcan (Emergent BioSolutions): While Emergent BioSolutions is the primary marketer of the Narcan nasal spray, the API production is often managed through their internal manufacturing capabilities or contracted third-party manufacturers.
• Fresenius Kabi: This company is a significant producer of injectable naloxone hydrochloride and a supplier of the API for various formulations.
• Akorn: Akorn has been involved in the production of naloxone hydrochloride products, including generic versions.
• Bausch Health Companies: Bausch Health, through its subsidiary Amneal Pharmaceuticals, also has a presence in the naloxone hydrochloride market.

The API manufacturing process for naloxone hydrochloride typically involves multi-step chemical synthesis starting from precursor molecules. Key intermediates and synthetic routes are often protected by patents, influencing who can produce the API and how.

What is the Patent Landscape for Naloxone Hydrochloride?

The patent landscape for naloxone hydrochloride is multifaceted, encompassing patents on the molecule itself, its synthesis, and its various formulations and delivery devices.

Original Composition of Matter Patents

The original patents covering naloxone as a chemical entity have long expired. Naloxone was first synthesized in the 1960s. The expiry of these foundational patents opened the door for generic competition and the development of new delivery methods and manufacturing processes.

Formulation and Delivery Device Patents

A significant portion of recent patent activity has focused on novel formulations and delivery devices to improve ease of use, patient compliance, and effectiveness.

• Nasal Sprays: The development of naloxone nasal sprays, such as Narcan, led to patents protecting the spray device, the specific formulation of naloxone within the spray, and methods of administration. These patents aim to ensure rapid absorption and ease of administration by untrained individuals. For example, patents often cover aspects like the spray actuator, the volume of delivered spray, and the concentration of naloxone hydrochloride.
• Auto-Injectors: Similar to epinephrine auto-injectors, naloxone auto-injectors have been developed to provide a pre-measured dose with a simple mechanism. Patents in this area cover the mechanical aspects of the auto-injector, safety features, and the integrated drug reservoir.
• Other Formulations: Research into alternative delivery methods, such as inhalable forms or sublingual formulations, has also resulted in patent filings, though these have seen less commercialization compared to nasal sprays and injections.

Process Patents

Process patents are crucial in the API manufacturing segment. These patents protect specific methods of synthesizing naloxone hydrochloride or its intermediates, often aiming for higher purity, improved yield, or reduced manufacturing costs.

• Chiral Synthesis: Naloxone is a chiral molecule. Patents may cover stereoselective synthesis routes that yield the desired enantiomer with high purity, avoiding costly separation steps.
• Impurity Profiling and Control: Manufacturers may patent novel methods for identifying and controlling specific impurities that arise during synthesis, ensuring compliance with regulatory standards.
• Crystallization and Polymorphism: Patents can also cover specific crystalline forms (polymorphs) of naloxone hydrochloride that offer advantages in stability, solubility, or ease of formulation.

Key Patent Holders and Litigation

The patent landscape is dominated by a mix of originator companies and generic API manufacturers.

• Emergent BioSolutions: As the developer and marketer of Narcan nasal spray, Emergent BioSolutions holds a significant portfolio of patents related to its product, including formulations and delivery devices. They have actively defended these patents against challenges.
• Teva Pharmaceutical Industries: Teva, a major generic drug manufacturer, has been involved in developing generic naloxone hydrochloride products and holds patents related to their manufacturing processes and formulations.
• Other Generic Companies: Numerous other generic pharmaceutical companies hold patents on their specific manufacturing processes for naloxone hydrochloride API and finished dosage forms.

Litigation often arises from patent infringement claims, particularly concerning the expiration of key patents and the introduction of generic alternatives. Companies seek to protect their market share by enforcing their intellectual property rights.

Regulatory Approvals and Market Dynamics

The approval of naloxone hydrochloride products by regulatory agencies like the U.S. Food and Drug Administration (FDA) is a critical factor in market access.

• ANDA Filings: Generic manufacturers must file Abbreviated New Drug Applications (ANDAs) with the FDA, demonstrating bioequivalence to the innovator product. This process often involves navigating existing patents through Hatch-Waxman Act provisions.
• Opioid Crisis Influence: The ongoing opioid crisis has significantly increased demand for naloxone hydrochloride. This has led to policy initiatives aimed at increasing access, including efforts to make naloxone available over-the-counter (OTC). The FDA’s 2023 approval of naloxone hydrochloride nasal spray for OTC sale is a landmark development that will likely reshape market dynamics and supplier requirements. This shift to OTC is expected to boost demand and potentially diversify the supplier base as new market entrants emerge.
• Pricing Pressures: Despite increased demand, pricing of naloxone hydrochloride has been a point of public and political concern. Efforts to control costs are ongoing, influencing R&D investment in process optimization and competition among suppliers.

Challenges and Opportunities in the Naloxone Hydrochloride Supply Chain

The supply chain for naloxone hydrochloride faces several challenges and presents distinct opportunities for stakeholders.

Challenges

• API Availability: A concentrated API supplier base can lead to vulnerability in the supply chain, particularly during periods of high demand or manufacturing disruptions. Ensuring consistent and robust API production is paramount.
• Regulatory Hurdles: Navigating the complex regulatory landscape for drug manufacturing and approval can be a significant barrier, especially for new entrants.
• Cost of Manufacturing: While efforts are made to reduce costs, the multi-step synthesis of naloxone hydrochloride API can still be expensive, impacting the final product price.
• Patent Expiries and Litigation: The expiration of key patents can lead to intense competition and price erosion, requiring manufacturers to focus on efficiency and innovation.

Opportunities

• Increased Demand: The widespread recognition of the opioid crisis and efforts to combat it are driving sustained and increasing demand for naloxone hydrochloride.
• OTC Market Expansion: The move to over-the-counter availability for naloxone nasal spray is a significant market expansion opportunity, necessitating scaled-up production and accessible distribution.
• Process Innovation: Developing more efficient, cost-effective, and environmentally friendly synthesis routes for naloxone hydrochloride API presents a competitive advantage.
• New Delivery Systems: Continued innovation in drug delivery devices, offering enhanced patient convenience and efficacy, can create new patentable intellectual property and market niches.
• Global Market Access: Expanding access to naloxone hydrochloride in underserved regions globally offers substantial growth potential.

Conclusion

The naloxone hydrochloride market is dynamic, shaped by patent expirations, regulatory shifts, and critical public health needs. A clear understanding of the key API suppliers, the patent landscape, and evolving market dynamics is essential for strategic decision-making in R&D, manufacturing, and investment within this vital pharmaceutical sector. The increasing accessibility through OTC approvals will likely accelerate demand and necessitate robust, adaptable supply chains.

Key Takeaways

• The naloxone hydrochloride API market is supplied by a limited number of specialized manufacturers.
• Patent protection for naloxone hydrochloride primarily focuses on formulations, delivery devices, and manufacturing processes, as the original composition of matter patents have expired.
• The shift to over-the-counter availability for naloxone nasal spray is a significant market expansion driver, expected to increase demand and potentially broaden the supplier base.
• Ensuring supply chain resilience, process innovation, and strategic patent management are critical for success in this evolving market.

Frequently Asked Questions

1. How has the recent move to over-the-counter (OTC) sales of naloxone nasal spray impacted the demand for naloxone hydrochloride API?

The FDA's approval of naloxone hydrochloride nasal spray for OTC sale in 2023 is projected to substantially increase demand for the API. This expansion into a broader consumer market, moving beyond prescription-only access, necessitates a scaled-up and more widely distributed supply chain to meet anticipated higher volumes.

2. What are the main types of patents relevant to naloxone hydrochloride products currently?

Current patent activity for naloxone hydrochloride largely centers on novel formulations designed for improved efficacy and ease of use, such as nasal sprays and auto-injectors. Additionally, process patents protecting specific synthetic routes for manufacturing the API with enhanced purity, yield, or cost-efficiency are highly relevant.

3. Are there any emerging or alternative suppliers of naloxone hydrochloride API gaining traction in the market?

While the market has historically been concentrated, the increased demand and the shift towards OTC sales may incentivize new entrants to develop capabilities in naloxone hydrochloride API manufacturing. However, establishing the necessary regulatory compliance and securing intellectual property for novel processes are significant barriers to entry.

4. What is the typical lead time for a pharmaceutical company to secure a new API supplier for naloxone hydrochloride, considering regulatory and quality assurance requirements?

Securing a new API supplier typically involves a rigorous qualification process that can take 6 to 18 months or longer. This includes audits of manufacturing facilities, review of quality management systems, validation of analytical methods, and batch testing to ensure compliance with Good Manufacturing Practices (GMP) and regulatory standards set by bodies like the FDA.

5. How do patent disputes typically play out in the naloxone hydrochloride market, and what is the impact on generic manufacturers?

Patent disputes often involve challenges to the validity of existing patents or claims of infringement. For generic manufacturers, these disputes can delay market entry if patents are upheld, or they can clear the path for generic competition if patents are invalidated or found not to be infringed. Successful navigation of the patent landscape through Paragraph IV certifications under the Hatch-Waxman Act is a common strategy for generic players.

Citations

[1] U.S. Food and Drug Administration. (2023). FDA Approves First Over-the-Counter Naloxone Hydrochloride Nasal Spray. [Press Release]. [2] Emergent BioSolutions. (n.d.). Narcan® Nasal Spray. Retrieved from [Emergent BioSolutions website or relevant product information page]. [3] Fresenius Kabi. (n.d.). Naloxone Hydrochloride Injection. Retrieved from [Fresenius Kabi website or relevant product information page]. [4] U.S. Patent and Trademark Office. (n.d.). Patent Database Search. (Specific patent numbers for naloxone synthesis, formulations, and devices would be cited here if specific examples were being analyzed). [5] Teva Pharmaceutical Industries. (n.d.). Product Information. (Relevant product portfolios or press releases concerning naloxone). [6] U.S. National Library of Medicine. (n.d.). PubChem Compound Summary for CID 440463, Naloxone Hydrochloride. Retrieved from [PubChem website]. [7] Hatch-Waxman Act. (21 U.S.C. § 355(j)).